Skip to main content
Print Save

Generic Advair HFA Availability

Last updated on Oct 6, 2021.

See also: Generic Advair Diskus

Advair HFA is a brand name of fluticasone/salmeterol, approved by the FDA in the following formulation(s):

ADVAIR HFA (fluticasone propionate; salmeterol xinafoate - aerosol, metered;inhalation)

  • Manufacturer: GLAXO GRP LTD
    Approval date: June 8, 2006
    Strength(s): 0.045MG/INH;EQ 0.021MG BASE/INH [RLD], 0.115MG/INH;EQ 0.021MG BASE/INH [RLD], 0.23MG/INH;EQ 0.021MG BASE/INH [RLD]

Has a generic version of Advair HFA been approved?

No. There is currently no therapeutically equivalent version of Advair HFA available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Advair HFA. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Actuation indicator for a dispensing device
    Patent 7,500,444
    Issued: March 10, 2009
    Inventor(s): Bonney; Stanley George & Brand; Peter John & Godfrey; James William & Rand; Paul Kenneth
    Assignee(s): Glaxo Group Limited

    An actuation indicator that includes a drum sub-assembly, which includes a rotatable actuation indicator wheel, a rocking, ratchet pawl for rotating the indicator wheel in a set direction and a rocking mechanism for the pawl driven by a slipping clutch arrangement, is described. The slipping clutch arrangement includes a slipping clutch spring engaged at one end to a pinion of a rack and pinion assembly and at a second end to the ratchet pawl.

    Patent expiration dates:

    • February 26, 2026
      ✓ 
      Drug product
    • August 26, 2026
      ✓ 
      Pediatric exclusivity
  • Actuation indicator for a dispensing device
    Patent 7,832,351
    Issued: November 16, 2010
    Inventor(s): Bonney; Stanley George & Brand; Peter John & Godfrey; James William & Rand; Paul Kenneth
    Assignee(s): Glaxo Group Limited

    An actuation indicator which includes a drums sub-assembly including a rotatable actuation indicator wheel, a rocking ratchet pawl for rotating the indicator wheel in a set direction and a rocking mechanism for the pawl driven by a slipping clutch arrangement, wherein the slipping clutch arrangement includes a slipping clutch spring engaged at one end to a pinion of a rack and pinion assembly and at a second end to the ratchet pawl is described.

    Patent expiration dates:

    • June 19, 2023
      ✓ 
      Drug product
    • December 19, 2023
      ✓ 
      Pediatric exclusivity

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer